Web9 apr. 2024 · Recent clinical trials of biologics targeting type I IFN signal showed efficacy in SLE [24,25,26].In a phase IIb trial of anifrolumab, a human monoclonal antibody to type I IFN receptor subunit 1, patients with high IFN signatures at baseline showed more favorable responses [].However, the following phase III studies revealed that high IFN signatures … WebObjectives To compare the pharmacokinetics (PK), safety and tolerability of subcutaneous (SC) and intravenous anifrolumab, an anti–type I interferon receptor monoclonal antibody in development for SLE, in healthy volunteers. Methods In this Phase I randomised, placebo-controlled study, 30 adults were assigned to three treatment cohorts …
Preclinical Vaccines Development Lead - LinkedIn
WebChronic activation of the type I interferon (IFN) pathway plays a critical role in systemic lupus erythematosus (SLE) pathogenesis. Anifrolumab is a human monoclonal antibody to the type I IFN receptor subunit 1, which blocks the action of type I IFNs. WebIntroduction. Systemic lupus erythematosus (SLE) is an autoimmune disorder with wide-ranging clinical manifestations. Although SLE varies patient to patient, one of the clinical hallmarks is the presence of autoantibodies and immune complexes, which contain host-derived nucleic acids, in the circulation [1-3].These immune complexes stimulate type I … full version of adobe acrobat
Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody…
Web17 mrt. 2003 · SLE patients, for example, have been shown to display anti-IFN antibodies in their serum that may interfere with ELISA measurements. Additionally, the antibody used for ELISA detection may not react with all the IFN species that may circulate in the blood. Web22 sep. 2024 · The feed-forward loop of type I interferons (IFNs) production and subsequent immunopathology of systemic lupus erythematosus (SLE) has been hypothesised to be disrupted with inhibition of IFNα or type I IFN receptor subunit 1 (IFNAR). Web3 aug. 2024 · FDA has approved AstraZeneca’s Saphnelo, a type I interferon receptor antibody for treating systemic lupus erythematosus. On Aug. 2, 2024, AstraZeneca announced that FDA approved Saphnelo (anifrolumab-fnia), a type I interferon (type I IFN) receptor antagonist, for treating moderate to severe systemic lupus erythematosus (SLE) … ginuwine the best man i can be